BrukerBRKR
Recorded

Bruker 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 3 minParticipants14

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, everyone, and welcome to the Bruker Corporation Third Quarter 2026 Earnings Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one on your touchtone phones. To withdraw your questions, you may press star and two. Please also note today's event is being recorded. At this time, I'd like to turn the floor over to Joe Kostka, Director of Investor Relations. Please go ahead. Good morning.

Joe KostkaDirector of Investor Relations

I would like to welcome everyone to Bruker Corporation's Third Quarter 2026 Earnings Conference Call. My name is Joe Kostka, and I am the Director of Bruker Investor Relations. Joining me on today's call are our President and CEO, Frank Laukien, and our EVP and CFO, Gerald Herman. In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at ir.bruker.com. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on slide two of the presentation.

Joe KostkaDirector of Investor Relations

During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics, or supply chains. The company's actual results may differ materially from such statements. Factors that might cause such differences include, but are not limited to, those discussed in today's earnings release and in our Form 10-K for the period ending December 31, 2025, as updated by our other SEC filings, which are available on our website and on the SEC's website. Also, please note that the following information is based on current business conditions and on our outlook as of today, November 4, 2026.

Joe KostkaDirector of Investor Relations

We do not intend to update our forward-looking statements based on new information, future events, or for other reasons, except as may be required by law prior to the release of our fourth quarter and full year 2026 financial results expected in February 2027. You should not rely on these forward-looking statements as necessarily representing our views or outlook as of any date after today. We will begin today's call with Frank providing an overview of our business progress. Gerald will then cover the financials for the third quarter of 2026 in more detail and comment on our full year 2026 financial outlook. Now, I'd like to turn the call over to Bruker CEO, Frank Laukien.

Frank LaukienPresident and CEO

Thank you, Joe. Good morning, everyone, and thank you for joining us on today's third quarter 2026 earnings call. Bruker continues to drive significant advances in post-genomic disease biology, solutions, and drug discovery, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These foundational advances in disease biology, together with strong growth drivers in specialty infectious disease diagnostics and in our deep tech and semiconductor metrology franchise, are expected to lead to significant revenue growth, acceleration, and further margin expansion. Bruker's positive bookings trends continued in the fifth consecutive quarter of Bruker Scientific Instruments, or BSI, book-to-bill greater than one, as we see increasing strength in most of our end markets, and I will highlight three areas in particular.

Frank LaukienPresident and CEO

First, U.S. academic and government, or Acad Gov. In the third quarter, our BSI organic bookings in the U.S. Acad Gov market grew in the double digits percentage year-over-year. This was the first quarter with year-over-year bookings growth in U.S. Acad Gov since the NIH funding disruption in 2025. The prior year comparison was a weak one, but this is nonetheless encouraging. By the way, we also expect year-over-year organic bookings growth in U.S. Acad Gov in the fourth quarter. One could speculate that last night's blue wave in the midterms could also bode well for U.S. Acad Gov funding in fiscal 2027 and beyond. Second, China. BSI organic bookings in China were up over 20%, both in the third quarter and year to date. This consists of broad-based demand strength, as almost all of our BSI end market orders in China grew nicely.

Frank LaukienPresident and CEO

Third, year to date, we've seen greater than 30% organic bookings growth in BSI semicon metrology markets in the quarter. This robust order growth is being fueled by the AI mega trend, which requires our metrology solutions for logic chip foundries, high bandwidth memory, and advanced packaging. While the lead times on these orders are longer than most of our life science tools, we expect to see these semi orders convert into revenue mostly in fiscal year 2027 and some in fiscal year 2028. Speaking of AI, artificial intelligence, in August, we started a strategic collaboration with, and we did a minority investment in Atinary Technologies, a pioneer of self-driving labs and agentic AI-driven chemistry R&D. Atinary integrates our Chemspeed lab automation and Bruker analytical measurement instruments into its agentic AI workflows.

Frank LaukienPresident and CEO

The Atinary lab in Boston includes Chemspeed robotics and Bruker benchtop NMR for small molecule synthesis and catalysis in pharmaceutical R&D and process development. All right, let's dive into the numbers. Let's turn to slide four now. For the P&L performance in the third quarter, where we achieved significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution. Our third quarter 2026 reported revenues of $874 million increased 1.6% year-over-year, with organic growth of 0.7%. Our third quarter 2026 non-GAAP gross and operating margins were 51.3% and 16.3% respectively, both up significantly year-over-year. Our Q3 2026 diluted non-GAAP EPS was $0.56, up 24% from Q3 2025. Moving to slide five, our year-to-date nine months Q3 2026 revenues increased by 3.1% to $2.54 billion, with organic revenue essentially flat.

Frank LaukienPresident and CEO

Our year-to-date non-GAAP gross margin, operating margin, and EPS were all up nicely year-over-year, and their year-to-date performance is summarized on slide five. As Gerald Herman will explain in more detail shortly, in Q3 and year-to-date, our free cash flow also has improved considerably, and we have made excellent progress with deleveraging. Please turn to slides six and seven now, where we highlight the year-to-date third quarter performance of our now reorganized three Bruker Scientific Instruments groups and of our BEST segment, all on a constant currency, or CER, and year-over-year basis. Year-to-date, the Biosystems Group revenue was $1.2 billion, up low single digits percentage year-over-year in CER. Strength in biopharma and translational research was partially offset by weakness in Acad/Gov.

Frank LaukienPresident and CEO

Biosystems saw strong CER growth in IR/Raman spectroscopy and in mass spectrometry, driven in part by the TOFWERK acquisition, which was partially offset by softness in NMR. Year-to-date 2026, our newly elevated Microbiology and Infection Diagnostics Group had revenues of $396 million, which increased in the low single digits percentage, driven primarily by robust molecular diagnostics revenue growth. Turning to slide seven. Year-to-date, Bruker Nano revenue was $770 million, with a low single digits percentage CER decline. Robust year-to-date growth in semi metrology and biopharma was offset by weakness in Acad/Gov and industrial. Semi revenues were down double digits in the third quarter, primarily driven by our previously communicated pushouts of semi metrology instruments from the third quarter.

Frank LaukienPresident and CEO

We had been very explicit about that in our Q2 earnings call when Gerald Herman gave Q4 color that we expected the $20 million pushout from Q3 in semi metrology. Finally, year-to-date, BEST revenues were up 8.3% in CER, net of intercompany eliminations, with strong growth in research instruments, or RI, and solid growth also in superconductors. Moving to slide eight, we highlight our recent acquisition of MIMETAS, a leading humanized organ-on-a-chip, or NAM, platform. NAM stands for New Approach Methodologies, a commonly used term in the industry and also by the FDA. I will let you read some of the background on MIMETAS. I think it is a reading slide rather than me going through every bullet.

Frank LaukienPresident and CEO

But I think it is very important to get the higher-level perspective that in addition to multi-omics and spatial and structural biology and AI-augmented drug discovery, one of the pain points and one of the reasons for the failure rates of so many drugs when promising drugs gets translated from mouse models or animal models to humans, are toxicities, are off-target toxicities that are unique to humanized models and human physiology. MIMETAS, with its humanized organs-on-a-chip, which can be nicely automated, which have many disease models, and are poised for very significant double-digit growth with high gross margins. We think are probably the best type of systems of this type on the market, which is why after extensive research on that market, we acquired a majority in MIMETAS.

Frank LaukienPresident and CEO

We're very excited, and we think this will complement our multi-omics spatial biology, structural biology in drug discovery, in particular drug discovery and development, in a very important way. It's a high priority for just about every biopharma company. On slide nine, we touch on a few recent advances in functional proteomics with novel workflows for drug discovery and disease biology launched at the recent international HUPO conference in Singapore. Again, I will not read every bullet, but we had very significant further advances in this MultiDIA method on our timsTOF for bottom-up proteomics, for plasma proteomics, single-cell proteomics, where we see in that net more peptides and protein groups, and also more proteoforms, sequence variants, and all the other things that traditional MS-based methods or the affinity methods simply cannot see. But they're functionally very important for better agentic AI frontier models or better drug discovery.

Frank LaukienPresident and CEO

On the right-hand side, our timsOmni continues to be a very successful system in the market with significant orders. And here are new workflows that are very, very important, one in glycobiology, where with our unique trapped electron-based fragmentation, I won't go into technical details, but it's really crucial to do this at scale, at speed, and in very sensitive manners. And glycobiology is tremendously important, but has been traditionally very difficult to study. Moreover, oligonucleotides and native RNA analysis is another important area, whether mRNA is a drug target or a potential RNA drug, and the instrument can perform outstanding workflows now in this area as well. We think this bodes well for further rapid adoption in academic medical centers, which have good funding, as well as in pharma companies and biotech companies. All right, that about does it for me.

Frank LaukienPresident and CEO

In summary, the third quarter, we achieved significant margin expansion and non-GAAP EPS growth, and our positive booking trends continued. Our BSI organic bookings and BSI backlog are both up mid-single digits percentage year to date. This helps de-risk our fourth quarter and sets us up for meaningful further performance improvements and growth acceleration in fiscal year 2027 and beyond. Let me turn the call over to our CFO, Gerald.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day